ClinicalTrials.gg
CompletedNCT00034580Updated Jul 19, 2006

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

A Phase 4 interventional study of olanzapine and risperidone in Bipolar Disorder, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2006-07-19.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.

Enrollment
5th of 28
326 · median 120
Started
2001
with 2 others
Phase 4
19 of 28
none open now
Registered
1st of 28
by date
Lead sponsor
13 of 28
Eli Lilly and Company

Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 5th largest by enrollment, is one of 3 that started in 2001, is one of 19 in phase 4, and was the 1st registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing olanzapine in Bipolar Disorder as a file.
02

Study summary

This is a research study comparing the safety and efficacy of two active study medications for the treatment of bipolar I disorder.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Bipolar I Disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject, 18-70 years of age
  • Female subjects of must be using a medically accepted means of
  • Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
  • Subjects must be considered reliable

Exclusion criteria

Exclusion:

  • Female subjects who are either pregnant or nursing
  • Uncorrected hypothyroidism or hyperthyroidism
  • Narrow-angle glaucoma
  • Subjects who present a serious and immediate risk of endangering him or herself
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
326 participants

Interventions

06

Study locations

21 sites
  • Berkley, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • San Marcos, California, United States
  • Torrance, California, United States
  • Denver, Colorado, United States
  • Middleton, Connecticut, United States
  • Washington, District of Columbia, United States
  • Winter Park, Florida, United States
  • Boise, Idaho, United States
  • Hoffman Estates, Illinois, United States
  • Natick, Massachusetts, United States
  • St Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Clementon, New Jersey, United States
  • Olean, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Madison, Tennessee, United States
  • Houston, Texas, United States
  • Richmond, Virginia, United States
  • Roanoke, Virginia, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2001 and a completion of Aug 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2002
First posted
May 1, 2002
Start
Aug 2001
Completion
Aug 2002
Last update
Jul 19, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 19, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00034580
First posted
May 1, 2002
Start date
Aug 2001
Completion
Aug 2002
Last update
Jul 19, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion